Alveolar Macrophage Programming Following Endotoxin Exposure

ConditionARDS, Human
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorNational Jewish Health

About this trial

The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).

Eligibility criteria

Qualifiers

Written, informed consent

Age 18-50

Disqualifiers

Current or recent illness (past 2 weeks)

Presence or prior history of cardiac, pulmonary or systemic disease

Bleeding disorder, use of systemic anticoagulants or antiplatelet therapy

American Society of Anesthesiology (ASA) class 2 or greater

Trial design

Treatments tested in this trial

  • bronchoscopy with intrabronchial administration of lipopolysaccharide

Treatment groups

25 Participants
are divided into 1 treatment group

Sponsors and collaborators